Therapeutics Solution International

Therapeutic Solutions International is a U.S.-based micro-cap regenerative medicine and immunotherapy company focused on adult stem cell therapies, cancer immunotherapy platforms, and immune-modulating nutraceutical products. Its lead technology appears to be JadiCell, an umbilical cord-derived mesenchymal stem cell product being developed for severe lung and neurodegenerative indications, while the company also references StemVacs-based cancer vaccine programs and nutraceutical brands such as QuadraMune. The company has operated through a number of subsidiaries and partial subsidiaries, including entities tied to neuroscience, pulmonary disease, and cell-therapy manufacturing. Therapeutic Solutions International was publicly traded under the symbol TSOI on OTC markets, but in 2025 disclosed plans to voluntarily delist and terminate its SEC registration, so it remains active as an operating entity but is no longer a conventional fully reporting public biotech. Overall, it is a small, highly promotional early-stage company with limited revenue and a broad but fragmented pipeline spanning regenerative medicine, immunology, and supportive health products.